U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H25N5O2.ClH
Molecular Weight 439.938
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DONITRIPTAN HYDROCHLORIDE

SMILES

Cl.NCCC1=CNC2=C1C=C(OCC(=O)N3CCN(CC3)C4=CC=C(C=C4)C#N)C=C2

InChI

InChIKey=ZXENQGQAPOYDOJ-UHFFFAOYSA-N
InChI=1S/C23H25N5O2.ClH/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19;/h1-6,13,15,26H,7-12,16,24H2;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C23H25N5O2
Molecular Weight 403.4769
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11575714

Donitriptan hydrochloride (F 11356) was developed by Pierre Fabre as a brain penetrant 5-HT1B/1D agonist. Which inhibits capsaicin-induced external carotid vasodilation and produces selective carotid vasoconstriction in various animal species. In January 2001, donitriptan had completed phase I trials for migraine and was scheduled to enter phase II development, but before development in phase II, this drug was discontinued.

CNS Activity

Curator's Comment: Known to be CNS penetrant in guinea pigs. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.44 null [pKi]
9.32 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

guinea pigs: Drugs were administered in 1% methyl cellulose in distilled water
Route of Administration: Oral
In C6 rat glioma cells expressing human 5-HT1B or human 5-HT1D receptors, F 11356 (DONITRIPTAN) was the most potent compound in inhibiting forskolin-induced cyclic AMP formation (pD2 = 8.9 and 9.6), and in contrast to tryptamine and derivatives, it produced maximal enhancement of [35S]guanosine-5'-O-(3-thio)triphosphate-specific binding equivalent to 5-HT. F 11356 was equipotent to 5-HT (pD2 = 7.1 versus 7.2) and more potent than tryptamine derivatives in contracting rabbit isolated saphenous vein. In isolated guinea pig trigeminal ganglion neurons, F 11356 was more potent (pD2 = 7.3 versus 6.7) and induced greater increases in outward hyperpolarizing Ca2+-dependent K+ current than sumatriptan.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:45:44 GMT 2023
Edited
by admin
on Sat Dec 16 10:45:44 GMT 2023
Record UNII
XTD13T14MR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DONITRIPTAN HYDROCHLORIDE
Common Name English
PIPERAZINE, 1-(((3-(2-AMINOETHYL)-1H-INDOL-5-YL)OXY)ACETYL)-4-(4-CYANOPHENYL)-, MONOHYDROCHLORIDE
Systematic Name English
F-11356
Code English
BENZONITRILE, 4-(4-(2-((3-(2-AMINOETHYL)-1H-INDOL-5-YL)OXY)ACETYL)-1-PIPERAZINYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
197705
Created by admin on Sat Dec 16 10:45:44 GMT 2023 , Edited by admin on Sat Dec 16 10:45:44 GMT 2023
PRIMARY
CAS
170911-68-9
Created by admin on Sat Dec 16 10:45:44 GMT 2023 , Edited by admin on Sat Dec 16 10:45:44 GMT 2023
PRIMARY
FDA UNII
XTD13T14MR
Created by admin on Sat Dec 16 10:45:44 GMT 2023 , Edited by admin on Sat Dec 16 10:45:44 GMT 2023
PRIMARY
EPA CompTox
DTXSID60168973
Created by admin on Sat Dec 16 10:45:44 GMT 2023 , Edited by admin on Sat Dec 16 10:45:44 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY